Kane Biotech (TSE:KNE) has released an update.
Kane Biotech Inc. has announced the expansion of its revyve™ Antimicrobial Wound Gel product line, backed by up to $200,000 in funding from the NRC IRAP, to develop three new products. These products aim to increase the company’s market presence by offering solutions for different types of wounds and settings, which will potentially drive higher revenue through increased price points and volumes.
For further insights into TSE:KNE stock, check out TipRanks’ Stock Analysis page.
